Fmr LLC Has $400.30 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fmr LLC boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 12.1% in the third quarter, HoldingsChannel reports. The firm owned 12,635,653 shares of the company’s stock after purchasing an additional 1,365,570 shares during the quarter. Fmr LLC owned 0.15% of IDEAYA Biosciences worth $400,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of IDEAYA Biosciences by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock worth $182,355,000 after buying an additional 679,985 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new position in IDEAYA Biosciences in the 1st quarter valued at about $214,000. CANADA LIFE ASSURANCE Co lifted its position in IDEAYA Biosciences by 120.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 11,099 shares of the company’s stock worth $487,000 after acquiring an additional 6,069 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in IDEAYA Biosciences during the first quarter worth approximately $405,000. Finally, California State Teachers Retirement System boosted its holdings in shares of IDEAYA Biosciences by 19.0% during the first quarter. California State Teachers Retirement System now owns 57,535 shares of the company’s stock worth $2,525,000 after acquiring an additional 9,176 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Trading Up 1.4 %

Shares of NASDAQ:IDYA opened at $27.36 on Friday. The firm has a 50 day moving average of $29.53 and a 200-day moving average of $35.32. IDEAYA Biosciences, Inc. has a 12 month low of $25.20 and a 12 month high of $47.74. The stock has a market capitalization of $2.36 billion, a PE ratio of -11.74 and a beta of 0.86.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter last year, the company earned ($0.46) EPS. On average, research analysts predict that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. UBS Group began coverage on shares of IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a “buy” rating and a $50.00 target price for the company. Stephens began coverage on shares of IDEAYA Biosciences in a research report on Monday, November 18th. They set an “overweight” rating and a $51.00 price target on the stock. Finally, Citigroup cut their price objective on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 27th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IDEAYA Biosciences has an average rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.